TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.
TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.